Small molecule anti-cancer therapy developer BlossomHill (BLSM.US) sets IPO price at $15-17 per share, aiming to raise $125 millions
智通财经2026/08/04 09:01According to Golden Ten Data, BlossomHill Therapeutics, a biotechnology company focused on developing small molecule cancer therapies and currently preparing for phase II clinical trials, announced the terms of its initial public offering (IPO) on Monday. The company plans to issue 7.8 million shares in a price range of $15 to $17 per share, raising $125 million. BlossomHill Therapeutics intends to list on Nasdaq under the ticker symbol "BLSM".
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Watch Out: Massive Token Unlocks Are Coming for 14 Altcoins This Week—Here’s the Day-by-Day, Hour-by-Hour List
Iran's top security official says oil revenues are returning to the country
Crypto prices
More
